Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alb-IFN plus ribavirin versus peginterferon alfa-2a plus ribavirin for treatment-naive chronic hepatitis C genotype 1
ACTRN12607000093482Phase 3Not yet recruiting
- Sponsor
- Human Genome Sciences
- Start
- Dec 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of albinterferon alfa-2b, ribavirin and peginterferon alfa-2a in hepatitis C virus infection (3 arms), sponsored by Human Genome Sciences. Primary endpoint: Sustained virologic response. Planned start Dec 2006; status: not yet recruiting.
02
Drugs
albinterferon alfa-2bribavirinpeginterferon alfa-2a
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on ACTRN12607000093482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000093482.